InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Discover the complete record of transactions filed by Klein Lawrence Otto, Chief Operating Officer. Director active across 3 companies, notably CRISPR Therapeutics AG. Aggregated, 6 filings have been recorded. Breakdown: 0 buy · 1 sell. Total volume traded: €62k. Activity tracked since 12 October 2022. The latest transaction was disclosed on 16 March 2026 (Cession). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Klein Lawrence Otto
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
1,729 shares@ US$41.30100.0% of flowCommon StockSEC:0000907654-26-000033:0
76,700 shares0Common StockSEC:0000907654-26-000015:0
24,500 shares0Voting Common StockSEC:0001213900-22-063947:0
4,584 sharesCommon SharesSEC:0001209191-22-018611:0
26,667 sharesCommon SharesSEC:0001209191-21-068455:0
10,000 sharesCommon SharesSEC:0001209191-21-056092:0
6 of 6 declarations
About Klein Lawrence Otto
Lawrence Otto Klein is the Chief Business Officer and Chief Operating Officer at CRISPR Therapeutics AG. He oversees the company's commercial and strategic operations, playing a crucial role in implementing growth strategy. With a strong background in the biopharmaceutical sector, Lawrence Otto Klein is committed to advancing the company's objectives and maximizing its market impact.
